SPLITOAK STRATEGIES LLC

Lobbying for BRISTOL-MYERS SQUIBB · Global biopharmaceutical company

Filing 1st Quarter - Report

1st Quarter (Jan 1 - Mar 31) 2026 · District of Columbia · House · Senate · $60,000.00 income · posted Apr 20, 2026

Lobbying activity 1

Medicare/Medicaid

Value of prescription drugs and patient access Issues related to Medicaid, Medicare Parts B & D, MFN U.S. Competitiveness issues

Source: federal Lobbying Disclosure Act filing. Bills are parsed from the activity descriptions.